The Cancer Biomarkers Study Section reviews applications on the discovery, development, and validation of diagnostic biomarkers for early detection of cancers. The study section will also review applications on the discovery, development and small-scale validation of prognostic markers of cancer progression, recurrence, and response of therapy.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Strategies for discovering novel cancer biomarkers potentially associated with patient outcomes
- Employment of specific analytical techniques and/or global molecular profiling assays to identify novel biomarkers (DNA, RNA, protein, lipids, or metabolites) obtained from tumor tissue or bodily fluids
- Early detection of cancer, monitoring of its progression or response to therapy using available medical imaging approaches including but not limited to MRI, PET, MRS, fluorescence, and immunohistochemical assays
- Validation of new biomarkers using animal models and human materials
- Development of novel methods for biostatistical analysis, informatics, and modeling that facilitate the discovery, evaluation, and use of cancer markers
Shared Interests and Overlaps
There are shared interests with Cancer, Heart, and Sleep Epidemiology Study Sections – Panel A (CHSA) and Panel B (CHSB) . In particular, the review focus of CHSA and CHSB to determine predictors and biomarkers of diseases/conditions is overlapping with CBSS. Applications that address these areas with a focus on cancer may be assigned to CBSS.
There are shared interests with Cancer Immunopathology and Immunotherapy (CII) . Applications addressing the general area of immunologic therapies of cancer and/or modulation of the innate and adaptive immune responses to cancer cells will be reviewed in CII. Applications that deal with markers of response to immunologic therapy or immune response to cancers may be assigned to CBSS.
There are shared interests with Clinical Oncology (CONC) . Applications involving the validation of cancer biomarkers for detection, progression and response to therapy in the context of clinical patient-oriented research and therapeutic trials will be reviewed in CONC. Applications that deal with the same subject matter but uses animal models and/or cohorts of clinical samples in correlative studies may be assigned to CBSS.
There are shared interests with Developmental Therapeutics (DT) . Applications involving translational studies of NOVEL¬ antineoplastic agents and pre-clinical drug toxicity, pharmacokinetic/pharmacodynamic and biomarker studies of anticancer agents should be reviewed in DT. Applications that deal with the same subject matter but on development of markers of responses and toxicity of ESTABLISHED therapeutic agents may be assigned to CBSS.
There are shared interests with Medical Imaging (MEDI) . Applications involving the application and validation of in vivo imaging of humans and animals, including early phase clinical studies of medical imaging systems, molecular probes and contrast agents, software, molecular imaging techniques, and related technologies should be reviewed in MEDI. Applications that deal with the use (rather than full scale method development and validation) of imaging approach for early detection of cancer, monitoring of its progression or response to cancer therapy may be assigned to CBSS.
There are shared interests with Radiation Therapeutics and Biology (RTB) . Applications addressing the therapeutic interactions of ionizing radiation, radionuclides, electromagnetic radiation, and heat at the molecular, cellular, organ and patient levels should be reviewed in RTB. Applications that deal with the markers of response or resistance to radiation therapies rather than the in depth mechanistic studies of radiation/thermal interactions or treatment planning/delivery/dosimetry may be assigned to CBSS.